MINDCURE has released the initial version of its iSTRYM digital therapeutics platform and expects to begin full commercial deployment in Q1 of 2022.
MINDCURE has released the initial version of its iSTRYM digital therapeutics platform and expects to begin full commercial deployment in Q1 of 2022.
MINDCURE's proprietary ibogaine manufacturing has reached the second stage of development: assessing the quality of its synthetic ibogaine.
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.
MindMed Inc has become the first psychedelics company to successfully uplist to the NASDAQ. Who will be the second...???
MINDCURE updates investors on key elements of its business model, including its iSTRYM digital therapeutics platform and its emerging TBI research.
In 2020, investors were able to reap spectacular returns from psychedelic stock warrants. With a new rally starting in the sector, a there is a NEW opportunity in these warrants.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now